FMP

FMP

Enter

Agenus Inc. (NASDAQ:AGEN) Demonstrates Exceptional Capital Efficiency in the Competitive Biotech Landscape

- (Last modified: Nov 18, 2024 9:33 AM)

twitterlinkedinfacebook
blog post cover photo

Image credit: Google Images

  • Agenus Inc. (NASDAQ:AGEN) showcases a remarkable Return on Invested Capital (ROIC) of 302.53% and a Weighted Average Cost of Capital (WACC) of 80.76%, indicating efficient capital utilization.
  • Geron Corporation (NASDAQ:GERN) and Celldex Therapeutics, Inc. (NASDAQ:CLDX) display negative ROIC, highlighting inefficiencies in capital utilization.
  • BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has the least negative ROIC to WACC ratio among the peers, suggesting it is closer to covering its cost of capital.

Agenus Inc. (NASDAQ:AGEN) is a biotechnology company focused on developing immuno-oncology therapies. The company aims to create innovative treatments for cancer by leveraging its expertise in immune system modulation. Agenus operates in a competitive landscape alongside companies like Geron Corporation, Celldex Therapeutics, and BioCryst Pharmaceuticals, all of which are also engaged in the development of novel therapies.

Agenus Inc. demonstrates exceptional capital efficiency with a Return on Invested Capital (ROIC) of 302.53% and a Weighted Average Cost of Capital (WACC) of 80.76%. The resulting ROIC to WACC ratio of 3.75 indicates that Agenus is generating returns significantly above its cost of capital. This suggests that the company is utilizing its capital effectively, which is a positive indicator for investors.

In contrast, Geron Corporation (NASDAQ:GERN) shows a negative ROIC of -68.21% against a WACC of 6.84%, resulting in a ROIC to WACC ratio of -9.97. This negative ratio suggests that Geron is not generating sufficient returns to cover its cost of capital, indicating inefficiencies in capital utilization.

Similarly, Celldex Therapeutics, Inc. (NASDAQ:CLDX) has a negative ROIC of -24.19% and a WACC of 11.81%, leading to a ROIC to WACC ratio of -2.05. This further highlights inefficiencies in capital utilization, as the company is not generating returns above its cost of capital.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) also reports a negative ROIC of -11.14% with a WACC of 13.03%, resulting in a ROIC to WACC ratio of -0.85. Although still negative, BioCryst's ratio is the highest among its peers, suggesting it is closer to covering its cost of capital compared to Geron and Celldex. However, it still falls short of generating positive returns.

Other Blogs

May 14, 2024 11:41 AM - Sanzhi Kobzhan

The easiest way to calculate stock’s target price and why the target price is important.

A stock's target price, also known as its fair value, is an indication of what a share can cost based on the company’s forecasted financial statements. It is important to know a stock's fair value to find undervalued stocks with great growth potential. Let's consider how investment analysts calculat...

blog post title

May 24, 2024 9:30 AM - Rajnish Katharotiya

How to Access and Analyze Earnings Call Transcripts

Earnings call transcripts are invaluable resources for investors, analysts, and financial enthusiasts. They provide insights into a company's performance, strategy, and future outlook, making them essential for making informed investment decisions. With Financial Modeling Prep, Earnings Call Transcr...

blog post title

May 27, 2024 3:30 PM - Rajnish Katharotiya

The best 5 GPU stocks other than NVDA

In the ever-evolving world of technology, certain sectors have consistently demonstrated exceptional growth and innovation. The graphics processing units (GPUs) industry is one such sector, offering investors a golden opportunity for potentially high returns. In this blog, we'll delve into why inves...

blog post title
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep